New shot aims to stop stomach bug that sickens millions
NCT ID NCT06485258
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new inactivated rotavirus vaccine (CDC-9) in 50 healthy adults aged 18 to 45. The goal was to see if the vaccine is safe and triggers an immune response. Participants received three shots over several months and were monitored for side effects and antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ROTAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Children's Center - Vaccine Research Clinic
Atlanta, Georgia, 30322, United States